Skip to content


For a company of our size, we are aiming in oncology to become:


on rare cancers,
and action drivers


by creating open ecosystems, investing heavily in R&D and developing precision medicine

A three-pronged approach to our oncology strategy

  1. Target hard-to-treat cancers
    Guided by patient needs, we strive to develop major therapeutic innovations in areas where needs are greatest. We wish to initiate therapeutic progress where generally speaking needs are not yet met, known as hard-to-treat cancers, such as digestive cancers (stomach cancer, pancreatic cancer, and cholangiocarcinoma, a rare and aggressive form of bile duct cancer), glioma, or brain tumors, hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma) and pediatric cancers.
  2. Concentrate on promising and complementary therapeutic approaches
    Servier concentrates its R&D programs in oncology in two promising areas:
    • Immuno-oncology, to activate the immune system against cancer cells ;
    • Targeted therapies, to specifically target one of the biological mechanisms of cancer cells.
  3. Draw on a wide range of expertise
    Our teams boast a high level of expertise, which is why we encourage cross-divisional collaboration through our various research centers throughout the world. All our R&D centers work in a collaborative manner, pooling their remarkable expertise through cutting-edge technology platforms:
    • Our R&D center in Boston is located in the heart of one of the world’s most innovative health ecosystems ;
    • Symphogen in Denmark is our high quality monoclonal and bi-specific antibody center of excellence ;
    • Our future Servier R&D Institute at Paris-Saclay, which will open its doors in 2023

To step up the pace of research and development in innovative treatments, we unrelentingly promote and pursue open innovation with pharmaceutical labs, biotech companies, prestigious academic institutions and start-ups.

In oncology, we have formed around 40 research partnerships and collaborations.


7 oncology treatments available for patients throughout the world

Learn more about our oncology development projects

By patients’ side

Improving patients’ quality of life

At Servier, we work with patients at all stages of the medicine’s life cycle.

We have published a number of brochures and videos developed in collaboration with expert patients, patient representatives, carers and health care professionals. Designed for patients living with digestive cancers to support them, as well as their family, throughout their cancer journey, these materials form part of SHAPE,2 an international program launched by Servier in collaboration with Digestive Cancers Europe.

Movie about GI cancers
00:00 / 00:00
Brochures for patients

My Mood

“Looking after your emotional health for people with metastatic colorectal cancer”

Brochures for patients


“Getting more from your conversations with health care professionals” – for people with metastatic colorectal cancer

Brochures for patients


“Eating well with gastrointestinal cancer”


Brochures for patients


“Guiding you through the different stages of living with metastatic gastrointestinal cancer”

Brochures for patients


“A Practical Guide to Moving More for people with metastatic colorectal cancer”

Brochures for patients


“A guide to finding trustworthy information online related to gastrointestinal (GI) cancers.”


Photo of a child with leukemia in the hospital

Everything there is to know about acute lymphoblastic leukemia

This cancer, that involves the bone marrow, affects a particular type of white blood cells, lymphoblasts (lymphocytes at an early stage of development). It is the most common leukemia in children, although it affects all age groups.

Understanding acute myeloid leukemia

Acute myeloid leukemia (AML) is a rare disease which mainly affects the elderly. It is a blood and bone marrow cancer which develops rapidly without therapeutic treatment.

Photo of a leukemia patient in the hospital

Got a question?

Want to report a side effect?
Check out our Pharmacovigilance page.

[1] World Health Organization

[2] “Support Harmonized Advances for better Patient Experiences”